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a b s t r a c t
The nucleoprotein (NP) of the inﬂuenza A virus encapsidates the viral RNA and participates in the
infectious life cycle of the virus. The aims of this study were to ﬁnd the degree of conservation of NP
among all virus subtypes and hosts and to identify conserved binding sites, which may be utilised as
potential drug target sites. The analysis of conservation based on 4430 amino acid sequences identiﬁed
high conservation in known functional regions as well as novel highly conserved sites. Highly variable
clusters identiﬁed on the surface of NP may be associated with adaptation to different hosts and
avoidance of the host immune defence. Ligand binding potential overlapping with high conservation was
found in the tail-loop binding site and near the putative RNA binding region. The results provide the
basis for developing antivirals that may be universally effective and have a reduced potential to induce
resistance through mutations.
& 2014 Published by Elsevier Inc.
Introduction
The inﬂuenza A virus causes a respiratory disease resulting in
annually recurring epidemics affecting an estimated 3–5 million
people and about 250,000 to 500,000 deaths worldwide (WHO,
2009). At the same time the inﬂuenza virus causes substantial
losses among domesticated birds (Leibler et al., 2009). Apart from
epidemics, inﬂuenza A viruses have been responsible for devastat-
ing pandemics killing at least 40 million people in 1918/1919
(Spanish Flu, H1N1) (Johnson and Mueller, 2002) and less serious
pandemics in 1957 (Asian Inﬂuenza, H2N2), 1968 (Hong Kong
Inﬂuenza, H3N2), 1977 (Russian Inﬂuenza, H1N1) (Cox and
Subbarao, 2000) and the latest pandemic (Swine Flu, H1N1) killing
an estimated 284,000 people (Dawood et al., 2012). Inﬂuenza
pandemics seem to occur when a pathogenic animal-type virus
acquires the capability of efﬁcient human to human transmission
(Horimoto and Kawaoka, 2005), which may occur due to muta-
tions or reassortment of human and animal RNA segments (Lin
et al., 2000). A current threat, besides the avian H5N1 virus, is an
avian H7N9 virus emerging in China that has caused 104 con-
ﬁrmed infections including 21 deaths by April 2013 (WHO, 2013).
Due to the high mutation rate and emerging resistance against
neuraminidase inhibitors (Ferraris and Lina, 2008) and amanta-
dine/rimantadine (Rahman et al., 2008), it is of utmost importance
to investigate other viral proteins as potential drug targets for
example the non-structural proteins (Darapaneni et al., 2009).
The inﬂuenza A virus belongs to the family Orthomyxoviridae.
It is a lipid-enveloped virus with a negative-strand RNA genome
organized into eight separate segments, which code for more than
eleven proteins dependent on the particular virus strain (reviewed
e.g. in Das et al. (2010)). Based on the antigenic properties of the
proteins haemagglutinin and neuraminidase the virus is classiﬁed
in subtypes HxNy. Segment ﬁve encodes the nucleoprotein (NP).
The primary function of NP is to encapsidate the segmented RNA
and bind with the three polymerase subunits, PA, PB1 and PB2, to
form ribonucleoprotein particles (RNPs) for RNA transcription,
replication and packaging (Du et al., 2012). The molecular struc-
ture of NP from an H1N1 virus (Ye et al., 2006) and an H5N1 virus
(Ng et al., 2008) has been elucidated by X-ray crystallography. NP
is composed of a head domain, a body domain, and a ﬂexible tail
loop (Fig. 1A). In each RNP, the viral RNA wraps around individual
NP molecules, in an arginine-rich RNA-binding groove (Marklund
et al., 2012; Ng et al., 2008) (Fig. 1A). NP oligomers are formed by
insertion of the tail loop of one NP molecule into the tail loop
binding pocket of another, via a crucial salt bridge between Glu339
and Arg416 (Coloma et al., 2009; Shen et al., 2011).
Inﬂuenza NP is the most abundantly expressed protein during
the course of infection, with multiple functionalities including
viral RNA synthesis and RNP trafﬁcking, polymerase regulation
and interaction with cellular polypeptides, including actin (Li et al.,
2009; Portela and Digard, 2002). Various nuclear localisation
signals (NLS) in the amino acid sequence of NP are critical for
nuclear import of the whole polymerase complex (reviewed in
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Hutchinson and Fodor (2012)). The N-terminus contains an
unconventional NLS, which becomes deactivated after Ser-3 phos-
phorylation (Wu and Pante, 2009). A potential bipartite NLS was
identiﬁed in the RNA binding groove between residues 198 and
216 (Weber et al., 1998) and a third NLS between residues 320 and
400 was identiﬁed based on deletion studies (Wang et al., 1997).
Overall it appears that the N-terminal unconventional NLS is the
major determinant of nuclear import (Cros et al., 2005), while a
nuclear accumulation signal between residues 327 and 345
potentially acts to retain NP in the nucleus (Davey et al., 1985).
NP has been identiﬁed as a target for drug discovery, and some
potential inhibitors acting against the NP protein were identiﬁed,
namely nucleozin that triggered aggregation of NP (Kao et al.,
2010), NP oligomerisation inhibitors (Shen et al., 2011) and the
RNA-binding inhibitor naproxen (Lejal et al., 2013). Analyses of NP
sequences at the amino acid or nucleotide level have been
conducted previously. A large scale study by Xu et al. (2011) of
based on 5094 NP nucleotide sequences split into different
evolutionary lineages identiﬁed six highly variable sites and a
few hundred conserved sites, the number of which depend on the
evolutionary linage and methodology used to calculate conserva-
tion. A review article reported the fraction of conserved amino
acid residues in secondary structure elements (Ng et al., 2009), but
no clear deﬁnition of conservation was given. Most references to
sequence conservation of NP in the literature (e.g. Mena et al.
(1999), Ng et al. (2009)) go back to a study conducted by Shu et al.
(1993) based on multiple alignment of 49 sequences.
The aims of the current study were to identify the degree of
conservation of NP among all inﬂuenza A virus subtypes from all
hosts in order to identify sites of universal conservation. The
mapping of the conservation scores onto the three-dimensional
structure together with an analysis of the small-molecule binding
potential suggests potential binding sites for antivirals that may be
universally applicable without leading to resistance. Furthermore,
our results suggest highly conserved sites with unknown function
which could be further investigated experimentally.
Results
Inﬂuenza virus sequences
Initially 4430 sequences of inﬂuenza A virus NP of all subtypes
and hosts were obtained. After clustering of sequences at 99%
identity threshold, 815 sequences remained that showed at least
1% sequence difference. Among the sequences there were 33% from
human, 26% from swine, 15% from chicken and 12% from duck
hosts; the remaining 14% were from a variety of species including
turkey, quail, mallard, horse, dogs as well as a variety of birds.
Conserved amino acid residues
The evolutionary conservation of amino acid residues in the NP
protein were identiﬁed using the ConSurf server (Ashkenazy et al.,
2010; Landau et al., 2005). Conservation scores were obtained
Fig. 1. (A) Structure of NP showing tail loop (yellow), head (blue) and body domain (green). Residues contributing to RNA binding are shown in ball-and-stick representation.
(B), (C) Structure and amino acid sequence of NP, colour coded by conservation scores as indicated in the colour legend.
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between 0.78 (highest conservation) and 4.8 (highest variability)
and assigned to grades between 9 (highest conservation) and 1
(highest variability) by the ConSurf server. Highly conserved residues
(grades 8–9) and variable residues (grades 1–3) are shown in Table 1.
Conservation grades were mapped to the protein backbone (Fig. 1A
and B). Overall the protein is highly conserved with 59% of residues in
the highest conservation grades 7–9, while 21% of residues are highly
variable with grades 1–3. A signiﬁcant number of 38 residues high-
lighted in Table 1 show no variation at all among the 4430 sequences
analysed.
Fig. 1C and Fig. 2 show the conservation mapped onto the
protein structure. The ﬁrst N-terminal helix shows a pattern of
conservation that is mainly conﬁned to one face of the helix
starting with Ile25 (grade 8) followed by Ser28 (grade 9), Met32,
Ile36, Tyr40, Gln42-Glu46. Another helix inside the body domain
that packs against the single antiparallel beta-sheet present in NP
has high conservation at residues Gln58, Ser60 (grade 8), Thr62,
Met66 and Ser69 (all grade 9). The following loop until Glu81
contains several highly conserved residues, such as Glu73, Arg74,
Arg75, Asn76, and Glu80. Note that a part of this sequence from
Leu79–Gly86 was not resolved in the original structure, but is
based on computational modelling. This high conservation is
mirrored by an opposite loop from Gly169 (grade 9) to Ser176
(grade 8). Both loops overlook a highly conserved α-helix from
Gly132 to Thr147. The end of this α-helix marks the transition into
the head domain. Two short α-helices Thr151–Thr157 and
Asp160–Ser165 with highly conserved features precede the second
loop just described. This loop is followed by a four-helix bundle
from Gly185–Leu264 after which the chain transits into the body
domain. The four helix-bundle contains some variable as well as
highly conserved residues, notably Gly185, Arg208, Gly212,
Arg221, Cys223, Glu252, Glu254, Arg261, Ser262 and Ala263 are
all conserved at grade nine. Inside the body domain from Lys273
until Arg391 some occurrences of highly variable residues are
observed. The amino acid chain then forms the tail loop from
approximately Arg400 to Lys430. Notably, some residues in the tail
loop show high conservation at grades eight or nine, such as
Ser407, Gln409, Pro410, Phe412, Ser413, Val414, Gln415 and
Pro419. The tail-loop binding pocket is formed by residues not
adjacent in sequence and its conservation is shown in Table 3 and
discussed further in the next section. The tail loop is then followed
by another α-helix with highly conserved Ile445, Glu449 and
Ser450. The chain traverses again to the body domain, where it
reveals a well-resolved structure composed of largely non-
repetitive secondary structure elements. Very high conservation
is found in this region at Ser457, Gly460, Val463, Glu465, Ala471,
Val476, Pro477 and Ala493.
On the other hand we found clusters of highly variable regions.
Ser50, Gln52 and Phe313 form a small highly variable (grade 1)
cluster on the surface of the body domain. A continuous patch of
variable sites is formed by Arg98, Arg100, Asp101, Gly102, Lys103,
Val105, Glu372, Ala373, Met374, Asp375 and Pro318. Another area of
variable sites is formed by Thr350, Arg351, Ile353 and Tyr496 (Fig. 2).
A consensus sequence calculated from the multiple alignment
was compared to the human inﬂuenza A pandemic NP sequences
in Fig. 3. At residue 100 there is a striking difference between the
consensus sequence and pandemic sequences, namely the con-
sensus residue Arg100, is replaced by hydrophobic residues Ile and
Val in human pandemic sequences. At all other variable positions
the same or a similar residue to the consensus is found in at least
one of the pandemic sequences.
Table 1
Conserved residues (conservation grades 8–9) and variable residues (conservation grades 1–3) of the NP protein identiﬁed using the ConSurf server (Ashkenazy et al., 2010).
Residues in bold print do not show any variation.
Residue
classiﬁcation
NP protein
Conserved
(grades 8–9)
Ile25, Ser28, Val29, Met32, Ile36, Gly37, Tyr40, Gln42, Met43, Cys44, Thr45, Glu46, Asp51, Arg55, Gln58, Asn59, Ser60, Thr62, Met66, Ser69, Ala70,
Phe71, Asp72, Glu73, Arg74, Arg75, Asn76, Tyr78, Glu80, Pro83, Lys87, Asp88, Pro89, Lys90, Thr92, Gly93, Gly94, Tyr97, Arg106, Leu110, Lys113,
Trp120, Ala123, Asn124, Gly132, Thr134, His135, Met137, Ile138, His140, Ser141, Asn142, Leu143, Asn144, Asp145, Thr147, Arg150, Thr151, Ala153,
Leu154, Val155, Arg156, Gly158, Asp160, Pro161, Met163, Cys164, Ser165, Leu166, Met167, Gly169, Ser170, Thr171, Leu172, Pro173, Arg175, Ser176,
Ala178, Ala179, Ala181, Gly185, Gly187, Thr188, Met196, Arg199, Asn205, Phe206, Trp207, Arg208, Gly209, Gly212, Arg213, Ala218, Glu220, Arg221,
Cys223, Leu226, Lys227, Gly228, Lys229, Thr232, Ala233, Gln235, Met238, Asp240, Gln241, Arg243, Pro248, Asn250, Ala251, Glu252, Glu254, Arg261,
Ser262, Ala263, Arg267, Ala271, Lys273, Ser274, Val285, Gly288, Phe291, Ser297, Val299, Gly300, Asp302, Pro303, Gln308, Gln311, Ser314, Arg317,
Glu320, His324, Lys325, Gln327, Leu328, Ala332, Ala336, Ala337, Glu339, Asp340, Arg342, Phe346, Arg348, Gly349, Pro354, Arg355, Arg361, Ala366,
Thr378, Ser383, Tyr385, Ala387, Ile388, Ser392, Gln405, Ser407, Gln409, Pro410, Phe412, Ser413, Val414, Gln415, Arg416, Pro419, Thr424, Ala427,
Phe429, Glu434, Arg436, Asp439, Ile445, Met448, Glu449, Ser457, Phe458, Gly460, Gly462, Val463, Glu465, Ser467, Ala471, Val476, Pro477, Phe489,
Asp491, Ala493
Variable
(grades 1–3)
Ala22, Arg31, Val33, Gly34, Arg38, Ile41, Ser50, Gln52, Gly54, Ile61, Ile63, Arg77, Ser84, Ala85, Arg98, Arg100, Asp101, Gly102, Lys103, Val105, Ile109,
Tyr111, Glu114, Arg117, Ile119, Asn125, Glu127, Asp128, Met136, Ala146, Ile183, Val186, Met189, Val190, Ile194, Ile197, Ile201, Arg214, Ile217, Phe230,
Lys236, Met239, Ile253, Ile257, Leu259, Leu283, Asp290, Arg293, Ile301, Leu306, Phe313, Pro318, Ala323, Val329, Leu341, Val343, Ser344, Thr350,
Arg351, Val352, Ile353, Gln357, Leu358, Val363, Val371, Glu372, Ala373, Met374, Asp375, Ser377, Arg384, Arg391, Asn397, Gln398, Arg400, Ile406,
Val408, Asn417, Leu418, Arg422, Ala423, Ile425, Lys430, Asn432, Thr433, Arg446, Ser450, Arg452, Pro453, Val456, Leu466, Thr472, Asn473, Asp480,
Met481, Ser482, Asn483, Gly485, Asn492, Glu494, Glu495, Tyr496
Fig. 2. Spaceﬁll representation of the NP structure (PDB-id 2Q06) with conserva-
tion grades mapped on the structure. See Fig. 1 for colour legend. Signiﬁcant
residues discussed in the text are labelled.
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Small-molecule ligand binding potential
The binding potential of NP for small molecule drugs was
predicted based on clusters of energetically favourable interaction
sites with a methyl-probe (Q-SiteFinder (Laurie and Jackson,
2005)) and docking of a library of small organic solvent molecules
(FtMap (Brenke et al., 2009)). The spatial arrangement of binding
sites is shown in Fig. 4 for both methods.
The binding sites are mainly located in the body domain with
some sites at the interface between head and body domain. FTMap
identiﬁed a number of sites within the binding pocket of the
tail loop, namely F1, F2, F4, F4, F5, F9 (‘F’ denotes binding sites
Fig. 3. Multiple sequence alignment of a consensus sequence calculated from all sequences used in this study with sequences from inﬂuenza A pandemics and the sequence
of the protein structure 2Q06. The sequence alignment is coloured by conservation based on the BLOSUM62 matrix (Henikoff and Henikoff, 1992). The 2Q06 sequence is
coloured according to conservation as in Fig. 1.
Fig. 4. Ligand binding sites identiﬁed by FtMap (A) and Q-SiteFinder (B). The numbers indicate the ranking assigned by the algorithms, which ‘1’ denoting the highest ranked
binding site.
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identiﬁed by FTMap, while the number indicates the rank assigned
by the algorithm). Further binding sites F3 and F8 were found in
the RNA binding region, while F7 is located in a different region of
the protein. Q-SiteFinder identiﬁed binding sites in similar as well
as different locations. Similar binding sites are Q3 and Q7, which
are located in the tail loop binding pocket. The highest-ranked
binding site Q1 is located in the RNA binding region. Q4 and F7 are
in similar regions, while there is not much agreement between the
other binding sites.
An important aim of the present work was to identify binding
sites that are spatially close to conserved amino acid residues.
Table 2 identiﬁes residues, which are in close proximity of the
binding sites. The highest ranked sites have a large volume, thus
spatially distant residues are included. The number of residues
included in Table 2 does not relate to the ranking of binding sites,
but to the number of residues which are in close proximity based
on the arbitrary cut-off of 0.3 nm. As shown in Table 2, most
predicted binding sites are close to one or more highly conserved
residues, except F4, Q3, Q8 and Q9. Notably the three highest
ranked sites F1, F2 and F3 are in close proximity to conserved
residues, while two highest ranked sites of the ConSurf method Q1
and Q2 are close to conserved residues.
Discussion
Sequence conservation
The objective of this study was to determine the degree of
conservation of NP among all sequenced inﬂuenza A viruses
isolates and to identify small-molecule binding sites in conserved
regions, which may form potential target sites for future antiviral
drug discovery. The protein structure of NP was based on the
recently published X-ray structure (Ng et al., 2008) of an H5N1
isolate with the missing amino acids residues 79–86 build by ab-
initio modelling with the i-Tasser server (Zhang, 2008). Sequence
conservation may arise due to functionally important sites, such as
interaction sites or targeting signals, sites important in maintain-
ing the protein structure (Schueler-Furman and Baker, 2003) or on
the RNA level as packaging signals (Gog et al., 2007). Variable sites
on the other hand may arise due to adaptation to different hosts or
due to evolutionary pressure to escape the host immune system.
Signiﬁcant amounts of NP were detected on the surface of infected
cells, which enables the detection by the host immune system
(Yewdell et al., 1981).
In established functionally important regions we ﬁnd high
conservation, for example in the bipartite nuclear localisation
signal (residues 198 to 216) (Wang et al., 1997), Trp207, Arg208,
Gly209 and Gly212 are conserved at grade 9. In addition it was
shown that Arg204, Trp207 and Arg208 bind to the viral poly-
merase (Marklund et al., 2012). In the nuclear accumulation signal
(residues 327 to 345) (Davey et al., 1985) Ala332, Ala337 and
Glu339 are conserved at grade 9. Signiﬁcant conservation was
found near the putative RNA binding grove in two ﬂaps over-
looking a highly conserved α-helix (Fig. 1). Previously it was found
that mutation of Asp72, Arg74, Lys113, Arg156, Arg174, Arg175,
Arg195, Arg199, Lys325 and Arg361 to alanine impaired the
incorporation of viral RNA (Li et al., 2009). All of those residues
except Arg174 and Arg195 are conserved at grade 8 or 9. Another
region of conservation can be found in the tail loop (residues 402–
428), which facilitates NP oligomerisation by binding to a corre-
sponding pocket formed between the NP body and head domain.
Gln409, Pro410, Phe412, Gln415 and Pro419 in the tail loop are
conserved at grade 9, while many other residues including Arg416
show conservation at grade 8. The mutation Phe412Ala was shown
to decrease the transcription of viral RNA (Li et al., 2009). Fig. 5
shows the binding of the tail loop into a cavity between head and
body domain.
Table 3 shows the conservation grades of residues of the tail
loop binding pocket, which are in close contact with the tail loop.
Notable the mutation Arg267Ala decreased the assembly of the
viral NP by 50%, while the Glu339Ala completely abolished NP
formation (Chan et al., 2010). Also mutation of the highly con-
served Glu449 located near to the tail loop in the helix of the head
domain decreases assembly of NP (Chan et al., 2010). It was
recently shown that isolated NP exists in equilibrium between
monomers and trimers and mutations Arg416Ala, Glu339Ala
stabilise the monomeric form, while Tyr148Ala shifts the equili-
brium to the trimeric form Chenavas et al. (2013). Arg416 is
located in the tail loop and shows a limited residue variety of
Arg, Lys and Gly with a conservation grade of 8. While the wild-
type monomer cannot be crystallised, a crystal structure of the
Table 2
Amino acid residues within 0.3 nm of predicted binding sites. Conserved residues with grade 8 or 9 are shown in bold face.
FTMap ConSurf
Site Amino acid residues Site Amino acid residues
F1 Ser344, Ala387, Ile388 Q1 Tyr78, Ser141, Thr171
F2 Ser165, Val186, Ala263, Gly268, Ile270, Ser392 Q2 Asp145, Tyr148, Arg150
F3 Gln58, Thr62, Tyr97, Ile365 Q3 Phe304, Trp330, His334, Ile347
F4 His272, His334, Ser335, Thr390 Q4 Asp51, Gly54
F5 Ile388, Arg461, Gly462 Q5 Arg342, Phe479, Asn483, Glu484
F6 Ala337, Phe338, Glu339, Ser486, Phe489 Q6 Gln58, Thr62, Tyr97
F7 Tyr40, Gly54 Q7 Ser165, Phe488, Phe489
F8 Ala131, Thr134, His135, Lys273 Q8 Leu307, Ser310, Val312, Leu279, Leu381
F9 Glu339, Asp340 Q9 Tyr289, Arg305, Asn309
Q10 Arg74, Arg174, Arg175
Fig. 5. Illustration of the interaction between the tail loop and its binding pocket.
The tail loop is based on the structure PDB-ID 2IQH (Ye et al., 2006) that was ﬁtted
onto the 2QO6 structure analysed here.
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monomeric mutant Arg416Ala showed that the tail loop is folded
onto its own body domain covering the tail loop binding site
(Chenavas et al., 2013). Furthermore, Chenavas et al. (2013)
postulated that the wild-type monomer is stabilised by phosphor-
ylation of Ser165 and showed using biophysical measurements
that a phosphomimetic mutation Ser165Asp leads to a monomeric
NP. This explains the high conservation of Ser165 (Table 3) that
only allows for a substitution by a Thr residue in some virus
isolates.
Additionally we identiﬁed areas on the surface of NP that
showed signiﬁcant variation (Fig. 2). Some of the variation can
be explained by adaptation to different hosts. It was shown that
mutations of the residue 313 confers resistance to the human
interferon-induced Mx1 protein (Manz et al., 2013). Mx1 has a
known antiviral activity against RNA viruses by binding to their
ribonucleocapsid (Haller et al., 2007). In addition residues 53, 100,
283 and 289 were shown to cause Mx1 resistance (Manz et al.,
2013). Of those only residues 100 and 283 are highly variable,
while Gly53 is conserved at grade 7 and Tyr289 is conserved at
grade 6, albeit there was insufﬁcient data to reliably assign the
conservation of Tyr289. Notably, pandemic inﬂuenza strains have
hydrophobic Ile or Val at position 100, while the consensus is the
positively charged Arg residue (Fig. 3). The signiﬁcance of other
highly variable clusters remains to be established. Notably, NP was
detected on the surface of infected cells, which enables the
detection by the host immune system (Yewdell et al., 1981).
Evolutionary pressure to avoid the host immune system may
explain some of this variation.
Small-molecule ligand binding potential
A signiﬁcant binding potential for small molecule ligands was
found in the tail loop binding pocket. Some of the highest ranked
sites, such as F1 and F2, were found here in proximity of highly
conserved residues (Table 2). This pocket has already been
exploited for the development of inﬂuenza virus inhibitors with
the strongest inhibitory activity (IC) of IC50¼2.7 mM shown by an
organic molecule (Shen et al., 2011). Based on our results one can
predict, that compounds targeting this pocket are unlikely to be
become ineffective due to virus resistance, since residues in this
pocket are highly conserved among virus subtypes and different
host organisms. A study by Kao et al. (2010) identiﬁed nucleozin
and analogues as a replication inhibitor with an IC50 between 0.07
and 0.33 μM for different virus isolates. A mutation Tyr289His was
identiﬁed as the only mutation contributing to resistance of an
escape mutant after ﬁve passages of selection indicating that the
binding site for nucleozin is located close to Tyr289. This corre-
sponds to the binding site Q9 identiﬁed in the present study (Table 2),
which is not located close to highly conserved region explaining the
emergence of escape mutants in the previous study.
Another potential binding site for small molecule ligands in the
RNA binding region was detected as sites F3, F8 and Q1, Q6. These
binding sites are close to a highly conserved helix, thus resistance
against inhibitors is unlikely to develop. The residue Tyr78 close to
Q1 is located on a ﬂexible loop, which can enable the access of
small molecule ligands to Q1. It was shown that ﬂexibility of the
two loops overlooking Q1 is required for NP activity (Tarus et al.,
2012). Thus any ligand binding to Q1 that interacts with loop
residues such as Tyr78 could reduce loop ﬂexibility and inhibit
RNA binding. That binding site has not yet been explored for
development of inﬂuenza virus inhibitors. However, recently the
anti-inﬂammatory drug naproxen has been shown to inhibit RNA
binding to NP and reduced viral titres with EC50¼11 μM (Lejal
et al., 2013). Based on molecular docking and site-speciﬁc muta-
genesis a binding site in proximity to Q2 was detected. The
mutations Tyr148Ala and Arg361Ala abolished the ability of
naproxen to inhibit RNA binding. Furthermore, no escape mutants
were detected after six passages of selection, as it would be
expected based on our conservation analysis of the Q2 binding
site shown in Table 2.
Other binding sites are also in contact with conserved amino
acid residues, such as Q10 and F9. While these binding sites
received low ranks from the detection algorithm, the nucleozin
example mentioned above (Kao et al., 2010) shows that even low
ranking binding site have a potential to bind small organic
molecules, possibly due to a conformational change of the protein,
which the binding site detection algorithms do not take into
account.
Some lower ranking binding sites may be involved in NP–NP
interactions, since NP exists as oligomers in the ribonucleprotein
complex.
Conclusion
A study of 4430 nucleoprotein sequences reveals a high
sequence conservation that overlaps with potential binding sites
rendering the nucleoprotein an excellent drug-target for small-
molecule antiviral drug discovery. Targeting the tail loop binding
pocket or potential binding sites near the RNA binding region are
the most promising strategies for antivirals that are unlikely to
lead to resistance in the future, since the binding sites are
conserved among different subtypes and hosts. Furthermore,
antivirals targeting these sites are likely to be universally effective
against viruses of avian, swine or human origin.
Methods
Sequence analysis
The protein sequences of the inﬂuenza A virus NP were
obtained from the National Center for Biotechnology Information
(NCBI) inﬂuenza virus resource (Bao et al., 2008). Sequences from
all virus subtypes and all hosts were chosen. Sequence redundancy
was removed by identifying clusters of sequences at 99% identity
and replacing a cluster with a representative sequence using the
CD-HIT suite (Huang et al., 2010). After the removal of sequences
containing undeﬁned amino acid residues the remaining
sequences were subjected to multiple alignment with MUSCLE
software (Edgar, 2004a, 2004b) using an iterative reﬁnement until
convergence of the sum-of-pairs score was achieved, which yields
the most accurate alignment. After conversion of the alignment to
the Phylip format (Futami et al., 2008), a phylogenetic tree was
Table 3
Amino acid residues in the tail loop binding pocket
close (0.3 nm) to the tail loop.
Residue Conservation grade
Gln149 7
Ser165 9
Leu264 7
Arg267 9
Ile270 5
His272 9
Ser335 6
Phe338 6
Glu339 9
Arg342 8
Thr390 7
Gln459 4
Phe489 8
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calculated with PhyML 3.0 based on the maximum-likelihood
method (Guindon et al., 2010) using the inﬂuenza-speciﬁc amino
acid substitution model FLU (Cuong et al., 2010). Multiple
sequence alignments were visualised with Jalview (Waterhouse
et al., 2009).
Protein structure
The crystal structure of NP from the inﬂuenza A virus subtype
H5N1 (Ng et al., 2008) was obtained from the RCSB Protein Data
Bank (Berman et al., 2000) with the identiﬁer 2QO6. This structure
was chosen, because the number of missing residues (from 79 to
86) was less than in than in a similar NP structure from an H1N1
virus with the identiﬁer 2IQH (Ye et al., 2006). The coordinate ﬁle
was manually split into a monomer, and a continuous model from
Ala22 to Tyr496 was obtained from the i-TASSER server 2.0 (http://
zhanglab.ccmb.med.umich.edu/I-TASSER/) (Zhang, 2008) explicitly
specifying the structure of 2QO6 as a template. None of the
templates identiﬁed covered the missing region 79–86, thus
according to the i-Tasser protocol, ab-initio modelling was applied
with a knowledge-based force ﬁeld (Wu et al., 2007). The ﬁnal
protein structure used for further analysis was obtained by copy-
ing the structural information of residues Tyr78 to Lys87 obtained
from I-TASSER into the monomer crystal structure.
Conservation analysis
The conservation of amino acid residues was obtained and
projected onto the protein structure using the ConSurf 2010 server
(Ashkenazy et al., 2010; Celniker et al., 2013; Landau et al., 2005).
The ConSurf algorithm takes into account the evolutionary rela-
tionships between protein sequences giving a greater weight to
evolutionary more distant sequences. This is essential for produ-
cing meaningful conservation scores, since the protein sequences
show high similarity due to originating from the same species. The
protein structure pdb-ﬁle, the multiple sequence alignment and
the phylogenetic tree calculated with the FLU substitution model
(Cuong et al., 2010) were uploaded manually and the Bayesian
statistic method was chosen. The resulting conservation scores are
standard scores with an average of zero and a standard deviation
of one. A score below zero denotes higher than average conserva-
tion. Conﬁdence intervals of conservation scores were calculated
with Bayesian statistics (Mayrose et al., 2004). For assigning
conservation grades (1–9), the scores below and above zero are
divided into 4½ intervals each, which form the nine conservation
grades. The interval for the lowest conservation grade 1 is expanded
to include residues with the highest variability (Ashkenazy et al.,
2010). A table of detailed results including statistical conﬁdence
intervals is available as supporting information.
Binding site prediction
Potential binding sites were predicted by two different meth-
ods, namely computational solvent mapping with FTMap that
involves docking a library of small organic solvent-like molecules
to the protein structure (Brenke et al., 2009) and QsiteFinder that
scans the protein surface with a methyl van Waals probe for
favourable interactions (Fuller et al., 2009). Clusters of docked
solvent molecules in case of FTMap or clusters of methyl probes in
case of QSiteFinder can identify potential hot spots of binding. The
FTMap binding sites are ranked based on the number of over-
lapping clusters of solvent molecules, while the QsiteFinder bind-
ing sites are ranked according to the total interaction energy. Both
rankings implicitly take into account the volume of the binding
site. The predicted binding sites and conservation scores were
combined by manually transferring the coordinates of binding
sites to the coordinate ﬁle (pdb-ﬁle) obtained from the ConSurf
server. Protein structures with conservation scores and predicted
ligand binding sites are available as supporting information.
Figures of protein structures were prepared with Rasmol (Sayle
and Milnerwhite, 1995).
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